Polymorphisms of uridine glucuronosyltransferase gene and irinotecan toxicity: Low dose does not protect from toxicity

ecancermedicalscience

Volumn 8, Issue 1, 2014, Pages

  Tziotou, Marianna ^a   Kalotychou, Vassiliki ^a   Ntokou, Anna ^a   Tzanetea, Revekka ^a   Armenis, Iakovos ^a   Varsou, Marianna ^a   Konstantopoulos, Konstantinos ^a   Tsavaris, Nicolas ^a   Rombos, Yannis ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Dose; Irinotecan; Toxicity; Uridine glucuronosyltransferase (UGT)

Indexed keywords

DNA; FLUOROURACIL; FOLINIC ACID; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A7; IRINOTECAN; URIDINE;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EXON; FEBRILE NEUTROPENIA; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; GREECE; HUMAN; LABORATORY TEST; LEUKOPENIA; LOW DRUG DOSE; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; NAUSEA; NEUTROPENIA; PHYSICAL EXAMINATION; PROMOTER REGION; THROMBOCYTOPENIA; VOMITING;

EID: 84900540757     PISSN: None     EISSN: 17546605     Source Type: Journal    
DOI: 10.3332/ecancer.2014.428     Document Type: Article

References (21)

1. Ando Y et al (2000) Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis Cancer Res 60 6921-6 PMID: 11156391
2. Marcuello E et al (2004) UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer Br J Cancer 91 678-82 PMID: 15280927 PMCID: 2364770
3. Innocenti F et al (2004) Genetic variants in the UDP- glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan J Clin Oncol 22(8) 1382-8 DOI: 10.1200/JCO.2004.07.173 PMID: 15007088
4. Martinez-Balibrea E et al (2010) UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy Br J Cancer 103 581-9 DOI: 10.1038/sj.bjc.6605776 PMID: 20628391 PMCID: 2939780
5. Lankisch TO et al (2008) Gilbert's syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk Cancer Epidemiol Biomark Prev 17(3) 695-701 DOI: 10.1158/1055-9965.EPI-07-2517
6. Cecchin E et al (2009) Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan J Clin Oncol 27(15) 2457-65 DOI: 10.1200/JCO.2008.19.0314 PMID: 19364970
7. Ando M et al (2002) Genetic polymorphisms of the UDP- Glucuronosyltransferase 1A7 gene and irinotecan toxicity in Japanese cancer petients Jpn J Cancer Res 93 591-7 DOI: 10.1111/j.1349-7006.2002.tb01295.x PMID: 12036456
8. Carlini LE et al (2005) UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan Clin Cancer Res 11 1226-36 PMID: 15709193
9. Schulz C et al (2009) UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer World J Gastroenterol 15(40) 5058-66 DOI: 10.3748/wjg.15.5058 PMID: 19859999 PMCID: 2768885
10. Denlinger CS et al (2009) Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors Cancer Chemother Pharmacol 65(1) 97-105 DOI: 10.1007/s00280-009-1008-7 PMID: 19415281 PMCID: 2746259
11. Nakamura Y et al (2011) Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer J Thorac Oncol 6(1) 121-7 DOI: 10.1097/JTO.0b013e318200e4e8
12. Hoskins JM et al (2007) UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters J Natl Cancer Inst 99(17) 1290-5 DOI: 10.1093/jnci/djm115 PMID: 17728214
13. Hu ZY et al (2010) Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk Clin Cancer Res 16(15) 3832-42 DOI: 10.1158/1078-0432.CCR-10-1122 PMID: 20562211
14. Hu ZY, Yu Q and Zhao YS (2010) Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhea: a meta-analysis Eur J Cancer 46 1856-65 DOI: 10.1016/j.ejca.2010.02.049 PMID: 20335017
15. Liu X et al (2013) Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians Pharmacogenomics J 1-10 DOI: 10.1038/tpj.2013.10
16. Gennatas C et al (2006) A prospective randomized study of irinotecan (CPT-11), leucovorin (LV) and 5-fluorouracil (5FU) versus leucovorin and 5-fluorouracil in patients with advanced colorectal carcinoma J Chemother 18(5) 538-44 DOI: 10.1179/joc.2006.18.5.538 PMID: 17127232
17. Deeken JF, Slack R and Marshall JL (2008) Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics Cancer 113 1502-10 DOI: 10.1002/cncr.23777 PMID: 18720361
18. Toffoli G et al (2010) Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer J Clin Oncol 28(5) 866-71 DOI: 10.1200/JCO.2009.23. 6125
19. Gagnon JF et al (2006) Irinotecan inactivation is modulated by epigenetic silencing of UGT1A1 in colon cancer Clin Cancer Res 12(6) 1850-8 DOI: 10.1158/1078-0432.CCR-05-2130 PMID: 16551870
20. Yasar U et al (2013) Evidence for regulation of UDP- glucuronosyltransferase (UGT)1A1 protein expression and activity via DNA methylation in healthy human livers J Pharm Pharmacol 65 874-83 DOI: 10.1111/jphp.12053 PMID: 23647681
21. Kohle C et al (2003) Frequent co-occurrence of the TATA box mutation associated with Gilbert's syndrome (UGT1A1*28) with other polymorphisms of the UDP-glucuronosyltransferase-1 locus (UGT1A6*2 and UGT1A7*3) in Caucasians and Egyptians Biochem Pharmacol 65 1521-7 DOI: 10.1016/S0006-2952(03) 00074-1